American International Group, Inc. Allovir, Inc. Transaction History

American International Group, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.64 - $0.78 $138 - $169	-217 Reduced 0.02%	1,153,976 $877,000
Q4 2023 Feb 13, 2024	SELL	$0.68 - $2.39 $68 - $241	-101 Reduced 0.01%	1,154,193 $784,000
Q3 2023 Nov 13, 2023	BUY	$2.15 - $3.64 $11,253 - $19,051	5,234 Added 0.46%	1,154,294 $2.48 Million
Q2 2023 Aug 04, 2023	BUY	$3.17 - $5.82 $16,423 - $30,153	5,181 Added 0.45%	1,149,060 $3.91 Million
Q1 2023 May 12, 2023	BUY	$3.94 - $7.05 $1,178 - $2,107	299 Added 0.03%	1,143,879 $4.51 Million
Q4 2022 Feb 10, 2023	SELL	$4.7 - $9.98 $253 - $538	-54 Reduced -0.0%	1,143,580 $5.87 Million
Q3 2022 Nov 14, 2022	BUY	$4.13 - $8.79 $863 - $1,837	209 Added 0.02%	1,143,634 $9.02 Million
Q2 2022 Aug 12, 2022	SELL	$3.26 - $7.06 $348 - $755	-107 Reduced 0.01%	1,143,425 $4.46 Million
Q1 2022 May 13, 2022	SELL	$6.75 - $13.52 $6,952 - $13,925	-1,030 Reduced 0.09%	1,143,532 $7.72 Million
Q4 2021 Feb 11, 2022	SELL	$12.94 - $25.99 $6,081 - $12,215	-470 Reduced 0.04%	1,144,562 $14.8 Million
Q3 2021 Nov 12, 2021	BUY	$16.97 - $25.06 $2.37 Million - $3.5 Million	139,617 Added 13.89%	1,145,032 $28.7 Million
Q2 2021 Aug 13, 2021	SELL	$19.44 - $25.06 $14,132 - $18,218	-727 Reduced 0.07%	1,005,415 $19.8 Million
Q1 2021 May 07, 2021	BUY	$20.81 - $45.5 $1.99 Million - $4.36 Million	95,723 Added 10.51%	1,006,142 $23.5 Million
Q4 2020 Feb 12, 2021	BUY	$23.94 - $46.81 $21.5 Million - $42.1 Million	899,701 Added 8394.3%	910,419 $35 Million
Q3 2020 Nov 04, 2020	BUY	$21.05 - $42.7 $225,613 - $457,658	10,718 New	10,718 $295,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.